Biochemical nature of an Fc mu receptor on human B-lineage cells by unknown
Biochemical Nature of an Fcjc Receptor on
Human B-Lineage Cells
By Tatsuharu Ohno,* Hiromi Kubagawa,* Sheila K . Sanders,§ and
Max D . Cooper*t
From the 'Division of Developmental and Clinical Immunology, Departments of Medicine,
Pathology, Pediatrics, and Microbiology University of Alabama at Birmingham, and the
#Howard Hughes Medical Institute, Birmingham, Alabama 35294, and SLaboratory Medicine,
Yale University, New Haven, Connecticut 06510
Summary
An IgM-binding protein of -60 kD has been identified on activated B cells, but not on resting
and activated T cells, monocytes, or granulocytes. Here, we characterize this IgM-binding protein
as a receptor for the Fc portion (CH3 and/or CH4 domains) ofIgM molecules (FcAR) . The Fct.R
can be expressed as a cell surface activation antigen throughout the pre-B and B cell stages in
differentiation . Receptor expression is not directly linked with IgM production, as both u- pre-
B cells and isotype-switched B cells may express the FcjiR . The receptor molecules produced
by both pre-B andB cells are identical in size and are characterized as an acidic sialoglycoprotein
with 0-linked, but no Winked, oligosaccharide. The FcIAR is anchored to the surface ofB-lineage
cells via a glycosyl phosphatidylinositol linkage. The Fcp,R is thus the third member of a family
of Fc receptors expressed on B-lineage cells, and its preferential expression on activated B cells
suggests a potential role in the response to antigens .
R eceptors for the Fc portions of all Ig isotypes (FcR)t
have been identified on cells of theimmune system (for
review see references 1-3) . The binding of Ig molecules to
cell surfaceFcR can trigger immunologic functions that vary
according to their Ig isotype specificity and the cell type . IgG
antibodies mediate cellular cytotoxicity by macrophages and
NK cells (3, 4) and phagocytosis of opsonized particles by
macrophages and granulocytes (3, 5) . IgE antibodies induce
the release ofchemical mediators by mast cells and basophils
(6, 7) . Because the FcR are essential for multiple immune
system functions, understanding their structure and function
has become an important focus in immunology. Consider-
able progress has been made in elucidating the structural diver-
sity ofFc-yR and FcER, especially through the use ofmAbs
and gene cloning (for review see references 8-13), but FcR
for the other Ig isotypes are still largely operationally defined
entities .
Functional FcuR have been reported on subpopulations
of T and B cells in both humans and mice (14-22), and in-
direct evidence suggests that IgM bindingmay enhance lym-
phocyte responses to antigens and polyclonal mitogens (22-24) .
In an earlier study, we identified an IgM-binding protein of
' Abbreviations used in this paper : ALL, acute lymphocytic leukemia ; CLL,
chronic lymphocytic leukemia; DAF, decay-accelerating factor ; FcR, Fc
receptor ; GPI-PLC, glycosyl phosphatidylinositol-specific phospholipase
C ; rLT, r-Lymphotoxin ; SAC, Staphylococcus aureus Cowan I .
-60 kD on activatedB cells, but could not detect this mole-
cule on resting and activatedT cells, monocytes, or granulo-
cytes (25) . In the present study, we characterize the IgM-
binding protein further, show that it is truly an FcgR, and
demonstrate its expression as an activation antigen throughout
the pre-B and B cell stages in differentiation .
Materials and Methods
Antibodies.
￿
The following mouse mAbs were used in this study :
(a) MH-59-10 (mouse UK isotype), SA-DA4-4 ('YtK), LP-13B2-3
('y2,K), and LP-13A3-6 (y26K) are specific for human F. chains (25,
26) ; (b) BH-EB2-1 (AK), NC-BB2-6 (y,K), and GH-EA5-1 (y2,K)
are specific for human y chains (25, 27) ; (c) CH-EB6-8 (y,K) is
an anti-human a chain antibody (27) ; (d) 57 .1 (it,K) and 35.3 ('Y,K)
have anti-DNP specificity (25) ; (e) CIa (AK) is specific for a chicken
la determinant (28) ; (f) IA10 (y2,K, a kind gift ofDr. V. Nussen-
zweig, New York University School of Medicine, New York) is
specific for decay-accelerating factor (DAF ; reference 29) ; and (g)
Leu-16 ( ,ytK) is an anti-CD20 mAb (Becton Dickinson & Co .,
Mountain View, CA) . All mAbs with specificity for human Ig de-
terminants were purified from ascites fluid by affinity chromatog-
raphy on Sepharose 4B columns coupled with the appropriate human
Ig. Other mAbs, except for IA10 and Leu-16, were isolated byDEAE
ion-exchange cellulose- and Sepharose-6B gel filtration chromatog-
raphy as described (26, 27) . FITC-labeled or biotinylated, affinity-
purified goat antibodies specific for mouse Ig, Ft, or K determinants
and free ofcrossreactivity with human Ig (Southern Biotechnology
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In some experiments, biotinylated, affinity-purified 187.1 rat anti-
mouse K mAb (30) was used as the second antibody.
Preparation ofMyelorna Proteins, IgMFragments, andIgMDeletion
Mutants. HumanIgM, IgA, andIgGmyeloma proteins andnormal
IgG were purified from serum samples by euglobulin or salt frac-
tionation, DEAF ion-exchange cellulose, and UltrogelAcA22 gel
filtration column chromatography as described (26, 27, 31) . The
Fc5P and FabP . fragments were prepared from ahuman IgMrc prep-
aration as described by Plaut and Tomasi (32) . The purity of each
fragment was confirmed by SDS-PAGE analysis under both reducing
and nonreducing conditions andby ELISA using anti-it and anti-n
mAbs . For studies using IgM domain deletion mutants, culture
supernatants were obtained from the mouse hybridoma clones
secreting IgM with well-characterized H chain (CH) domain de-
letions : clone 43 (CHI deletion, HIoLIo), clone427 (CHI-2 deletion,
H2L2), and their parental cloneSp6.18 (intact IgM), and clone 128
(CHI-2 deletion, HL), clone 208 (CHI-3 deletion, HL), and 482
(CH4 deletion, H2L2) (33-35) (generous gifts from Dr. M. J.
Shulman, University of Toronto, andDr. G. Mr KShler, MaxPlanck
Institute forImmunology, Freiburg) . The concentration of IgM,
estimatedby ELISAusing rat anti-mouse KmAbforcoating plates
and alkaline phosphatase-labeled goat anti-mouse K antibody as
a developing reagent was adjusted to 0.05 mg/ml.
Cell Preparation and Activation . The preparation of blood
mononuclear cells from normal donors and the enrichment ofB
cells by depletion ofT cells with SRBC rosette formation and of
monocytes with adherence to plastic dishes have been described
elsewhere (25, 26) . Acuteandchroniclymphocytic leukemia (ALL
and CLL) populations (>95% purity estimated by immunophe-
notypic profiles) were obtained from patients' blood samples. The
hemopoietic cell lines used in this study are listed in Table I . All
were free of Mycoplasma when tested by Bisbenzimide H 33258
Fluorochrome staining (Hoeschst dye33258; Calbiochem-Behring
Corp., San Diego, CA). For cell activation, cells (0.7-1.0 x 106)
resuspended in 1 ml of RPMI 1640 containing 10% FCS, peni-
cillin (100 U/ml), streptomycin (100 Ftg/ml), and 5 x 10-s M
2-ME were cultured at 37°C for 16 h with or without the fol-
lowing stimuli : 0.1-100nMPMA, a mouseIgMmAb(CIa; 3-1,000
,ug/ml), 0.0001-0.1% heat-killed Staphylococcus aureus Cowan I
(SAC), a mitogenic anti-human Ic mAb (SA-DA4-4; 0.1-100 lug/ml), rIFN-a (Roche-Takeda Co., Tokyo, Japan), rIFN-(3 (Kyowa
Hakko, Tokyo, Japan), rIFN-y (Amgen Biologicals, Thousand
Oaks, CA), rIL2 (BIOgene Co. Ltd., Geneva, Switzerland), rIL4
(Immunex, Seattle, WA), rTNF (Genetech, San Francisco, CA),
or r-Lymphotoxin (rLT Genetech) at concentrations of 10-1,000
U/ml. In other experiments, cells were incubated with PMA (10
nM) or mouse IgM (100 hg/ml) for various intervals (0.5-72 h) .
Immunofluorescence Analysis ofCell Surface Molecules.
￿
For studies
ofIgM binding, viable cells (0.5-1.0 x 10 6) were incubated for
20 min at 4°C with or without 10 p .l of highly purified mouse
IgM mAbs with irrelevant specificities (CIa or 57.1; 0.1 mg/ml),
washed, and stained with 10 /Al of biotinylated goat anti-mouse
W antibody (0.05 mg/ml) or rat anti-mouse K mAb (0 .1 mg/ml)
as described (25, 31) . PE-labeled streptavidin (10 iul ; 0.01 mg/ml)
was used as a developing reagent. Cells were analyzed by flow im-
munocytofluorometry using a FACScan (BectonDickinson& Co.)
equipped with aConsort 30 data managing program. In an inhibi-
tion assay for IgMbinding, cells were incubated (30 min at 4°C)
with various inhibitor proteins before assay for IgMbinding. For
the expression ofCD20andDAFantigens, Leu-16 andIA10mAbs
were used as well as isotype-matched control mAbs .
Immunoprecipitation ofIodinated MembraneProteins.
￿
Activated cells
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Table 1.
￿
Expression of the IgM Receptor
MFI'
Cell type
￿
Cell line
￿
PMA (-)
￿
PMA (+)
Pre-B cell
￿
BLIN-1
￿
1 .5
￿
19 .8
697
￿
1 .3
￿
17.3
SMS-SB 1 .2 15 .2
Nalm6
￿
1 .4 3.5
207
￿
1 .1
￿
1 .3
B cell
￿
Raji
￿
1 .3
￿
5.9
Ramos
￿
1 .4 2 .5
Daudi
￿
1 .2
￿
1.8
CESS
￿
1 .4
￿
1.4
Dakiki
￿
1 .3
￿
1.2
Plasma cell
￿
RPMI 8226
￿
1 .0
￿
1.2
T cell
￿
Jurkat
￿
1 .2
￿
1.3
CEM6
￿
1 .1 1.4
Hut78
￿
1 .4 1.5
Myeloid U937
￿
1 .1 1.5
PLB985
￿
1 .3 1 .2
Erythroid K562
￿
1 .4 1.2
* The ratio ofmean fluorescence intensity betweenIgM binding andback-
ground .
(3 x 10') were surface labeled with 1 mCi Nal"I (Amersham
Corp., Arlington Heights, IL)by the lactoperoxidasemethod (36)
and lysed in 1 ml of 1% NP-40 in 50mM Tris-HCI buffer, pH
7.4, containing 150 mM NaCl, leupeptin (1 Fig/ml), antipain (2
,ug/ml), trasylol (10 U/ml), benzamidine (10 wg/ml), and 1 mM
PMSF (Mobay Chemical Co ., New York) . After centrifugation
(15,600g for 20 min at 4°C), IgM-binding molecules were iso-
lated from thecleared lysates by either the previously described solid
phase immunoisolation technique (25-27) or the following im-
munoadsorbent bead-mediated immunoprecipitation . Briefly, 1 ml
ofthe cell lysate was sequentially incubatedwith 100,al ofSepharose
4B coupled with human albumin (5 mg/ml of beads) and with
normal human IgG (5 mg/ml of beads) for 6-15 h at 4°C with
rotation . This precleared lysate was incubated with 20 pl of
Sepharose4B coupledwith ahumanIgMtc myelorna or aCIa(mouse
IgMtc) mAb (2.5 mg/mlofbeads) for 15 h at 4°C . After extensive
washingwith lysis buffer,boundmoleculeswere dissociated by ad-
dition ofLaemmli's sample buffer (37),and resolved by,SDS-PAGE
analysis using 10% acrylamide. For glycosidase digestion, IgM-
bound molecules were incubated at 37°C with : (a) N-glycanase
(Genzyme, Boston,MA)at 2-50U/ml for 16h; (b) neuraminidase
(Sigma Chemical Co .) at 0.05 U/ml for 12 h; or (c) neuraminidase
at 0.05 U/ml for 12 h and O-glycanase (Genzyme) at 4 U/ml for
12haccording to the manufacturer's recommendation. The digested
materials were then analyzedbySDS-PAGE . For two-dimensional
gel analysis, IgM-bound molecules were resuspended in 9.5 M
Urea/2% NP-40/2% Ampholines (pH range3.5-9.5)/5% 2-ME,
and separated first in tube gels according to isoelectric points, over-
laid onto slabs of SDS-PAGE, and then run in the second dimen-sion according to molecular weight as described by O'Farrell et
al. (38) .
Biosynthetic Analysis of IgM-R .
￿
Cells (3 x 10 7) preactivated
with PMA (10 nM for 12 h) were metabolically labeled with 'IS-
Met and 3'S-CyS (100 ACi each) for 6 h in the presence of PMA .
For inhibition ofWinked glycosylation, cells were incubated with
tunicamycin (2.5 14g/ml ; 1.5 h at 37°C), washed, and then labeled
in the presence ofPMA and tunicamycin . Radiolabeled IgM-R mol-
ecules were isolated from both the culture supernatant and cell ly-
sate (1% NP-40 1ysis buffer), and resolved by SDS-PAGE analysis .
Enzyme Treatment of Cells.
￿
PMAactivated cells (5 x 106/ml)
were incubated for 30 min at 37°C in 10mM Hepes-HBSS, pH
7.4, containing various amounts of glycosyl phosphatidylino-
sitol-specific phospholipase C (GPI-PLC; from Bacillus thuringiensis ;
enzyme activity: 0.35,uM/min/ml), a generous gift of Dr.M . G.
Low (Columbia University, New York) (39) . After treatment, cells
were washed with PBS containing5% FCS, centrifuged on a Ficoll-
Hypaque gradient to eliminate dead cells, and assayed for IgM-R
and cell surface antigens by flow immunocytofluorometry . In some
experiments, surface-iodinated cells were similarly treated with GPI-
PLC, and the treated cell pellet and the supernatant were subjected
to immunoprecipitation of IgM-R molecule and SDS-PAGE analysis.
Results
Cellular Distribution andRegulation ofIgM-R Expression .
￿
A
panel of hemopoietic cell lines representative of different
lineages and of different stages in B cell differentiation were
examined in order to confirm the B-lineage restriction of
IgM-R expression (25) and to identify a prime cell source
for isolation of the IgM-R molecules. The pre-B cell lines
(697, BLIN-1, and Nalm6) exhibited a slightly shifted immu-
nofluorescence profile for IgM binding (Fig . 1), but none of
the other cell lines constitutively expressed IgM-R in detect-
able levels. However, IgM binding was easily demonstrated
onPMAactivated pre-B cell lines (697, BLIN-1, SMS-SB >
Nalm 6) and to a lesser extent onPMAactivated B cell lines
(Raji > Ramos) (Fig . 1 and Table I) . Maximal IgM-R ex-
pression was obtained at a PMA concentration between 1
and 100 nM (Fig. 2A) . The induction ofIgM-R expression
by the cultured pre-B cells occurred as early as 16 h afterPMA
activation and persisted beyond 72 h without substantial cell
Log Fluorescence
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death (Fig. 2 B) . In agreement with previous findings (40-43),
these pre-B cell lines were found to express F, chains both
in the cytoplasm and on the cell surface in small amounts,
the surface level ofwhich was downregulated by PMA stim-
ulation (data not shown) . None of the cell lines of other
lineages (three T cell, three myeloid, and one erythroid) were
capable ofbinding IgM even after PMA activation (Table I) .
Unlike normal B cells (25), the 697 pre-B cells did not
express IgM-R after treatment with a mitogenic anti-1, mAb
(DA4.4 ; 0.1-100 lAg/ml) or SAC (0.0001-0.1%), or with a
variety of other stimuli, including rIFN-a, -I0, or -,y, rIL2
or -4, rTNF, and rLT (101-103 U/ml) . In contrast, both
mouse and human IgM induced the expression of IgM-R
on 697 pre-B cells in a dose-dependent manner (Fig. 2 A).
IgM-R expression was maximal within 30 min after incuba-
tion with IgM, whereas longer exposure to PMA was re-
quired for maximal stimulation (Fig . 2B) . Notealso the higher
level ofIgM-R expression induced by its natural ligand . This
upregulation by IgM was dependent on the continuous pres-
ence ofthe ligand, as removal ofIgM from the culture resulted
in a time-dependent decline ofIgM-R expressionby 697 pre-B
cells.
Fresh leukemic samples ofB-lineage cells (fourALL, eight
CLL) were examined for their IgM-binding capabilities. In
most cases, the leukemic cells were capable of binding IgM
at significant levels, and all ofthem exhibited enhanced binding
ofIgM after overnight culture with PMA (see Fig . 1) . This
result contrasts with the low or undetectable levels ofIgM-R
expression by unstimulated pre-B andB cell lines, but parallels
the IgM-R expression noted previously on subpopulations
of fresh tonsillar or splenic B cells (17, 25) . The results of
this survey also indicate that IgM-R expression is not directly
associated with the intracytoplasmic or surface expression of
IgM molecules, since one of the ALL samples had neither
cytoplasmic nor surface u, and two of the eight CLL samples
had undergone isotype switching: one expressed surface IgGltc
and the other surface IgA1X .
Characterization o,fIgM-RMolecules.
￿
To determine whether
IgM-R on pre-B cells are the same as the polypeptide chain
of -60 kD previously identified on activated B cells (25),
Figure 1 .
￿
Immunofluorescence analysis of IgM binding
by various types of B-lineage cells . Cells incubated with
or without PMA (10 nM for 16 h) were stained as de-
scribed in Materials and Methods . Solid lines represent
the immunofluorescence profiles of cells cultured with
PMA, and dotted lines represent the cells cultured without
PMA . Dashed lines represent control profiles, developed
with the secondary antibody, which were virtually iden-
tical for cells cultured with or without PMA . Note that
PMA consistently induces an increase in IgM-binding ca-
pacity for pre-B and B cells.
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. 1iodinated IgM-R molecules from the four pre-B cell lines
were examined bySDS-PAGE analysis. An IgM-binding mol-
ecule with an apparent Mr of 58,000 ± 3,000 (mean ± 1
SD from 30 experiments) was identified on all four pre-B
cell lines by using either mouse or human IgM as the ligand
(see Fig . 3) . The same molecular mass estimate was obtained
under both reducing and nonreducing conditions . The mo-
lecular size identity of IgM-R from pre-B and B cells was
confirmed on a gel in which theIgM-R isolated from different
cell sources (i .e ., PMA-activated, pre-B cell lines, IgMK/IgDK
ALL, and normal B cells) were subjected to electrophoresis
in adjacent lanes (data not shown) . In agreement with the
immunofluorescence results, PMA-activated pre-B cells yielded
a more intense 58-kD band than did unstimulated pre-B cells
(Fig . 3, lanes 6 and 7 vs. 2 and 3) . The inverse relation was
observed for the -78-kD p, H chain expressed on their cell
surface ; PMA-activated pre-B cells gave a less intense p, chain
band than did the unstimulated pre-B cells (Fig . 3, lane 5
vs . 1) . When an IgG1u anti-p, mAb was used to immuno-
precipitate the p. H chains on the surface of pre-B cells, a
protein with the same molecular mass as the IgM-R was
coprecipitated, suggesting (15) that the IgM-R may associate
with its crosslinked IgM neighbors (Fig. 3, lane 1) . Addi-
tional discrete proteins of45 and 18-22 kD were also coprecipi-
tated with p. chains on the pre-B cell line . The former is most
likely actin, while the latter represents the surrogate L chain
complex, thought to be encoded by Vpre-B and A5 genes
and to be human homologues of mouse w and t proteins
(44-48 ; Ohno et al ., manuscript in preparation) .
When isotype-switchedB CLL samples (IgG1a and IgA1A)
were examined for IgM-R molecules, the same 58-kD band
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Figure 2 .
￿
Effect ofPMA and IgM stimulation on the
expression of IgM-Rby the 697 pre-Bcell line . (A) Dose-
dependent induction of IgM-R expression . Cells were in-
cubated for 16 h with various doses of either PMA or
IgM, washed, then assessed for IgM binding by im-
munofluorescence as described in Materials and Methods.
In the case of incubation with mouse IgMK, biotinylated
rat anti-mouse K mAb was added immediately after
washing the cultured cells. Results were expressed as an
IgM-binding index, which was estimated by : (x ofstaining
ofPMA- or IgM-treated cells - x ofbackground control
staining of PMA- or IgM-treated cells)/(x of staining of
nontreated cells - x ofbackground control staining of
nontreated cells) ; where x indicates the mean fluorescence
intensity value. (B) Time course analysis ofPMA- and IgM-
induced IgM-R expression . Cells were incubated for
varying time intervals withPMA (10 nM) and mouse IgM
(100 hg/ml), washed, then examined for IgM-R expres-
sion as described above .
Figure 3 .
￿
PMA-induced upregulation of IgM-R expression on the 697
pre-B cell line. The 697 pre-B cells (3 x 107) incubated with or without
PMA (10 nM, 16 h) were labeled with 1 mCi Na1z5I, and their NP-40-
solubilized membrane lysates were added to wells precoated with the fol-
lowing mouse mAbs : lanes 1 and 5, SA-DA4-4 anti-human u (y l rc); lanes
2 and 6, CIa anti-chicken Ia (WK) ; lanes 3 and 7, 57.1 anti-DNP (FAK);
lanes 4 and 8, 35 .3 anti-DNP (71K). Bound materials were analyzed by
SDS-10% PAGE under reducing conditions. An IgM-binding molecule
of 58kD was also identified on the BLIN-1, SMS-SB, and Nalm 6 pre-B
cell lines after PMA activation by using either mouse or human IgM as
the ligand .was identified on both types ofPAM-activated CLL cells using
IgM mAbs regardless of their specificity (data not shown) .
mAbs of other isotypes but with the same specificity as the
IgM mAb did not precipitate this molecule.
To determine their glycosylation status, IgM-R were iso-
lated from either PMA-activated B-CLL or 697 pre-B cells,
digested with various glycolytic enzymes, and then analyzed
bySDS-PAGE . The molecular mass oftheIgM-R from both
cell sources was not altered by treatment with N-glycanase
(2-50 U/ml), while the size of the surface P. H chain as a
control was reduced to -68 kD (data not shown) . This sug-
gests that N-linked oligosaccharides are not present on IgM-R
molecules, since N-glycanase-resistant Winked carbohydrates
have not been reported (49) . Removal of sialic acid residues
with neuraminidase from the 58-kD IgM-R molecule resulted
in a decrease of molecular mass to 51 kD (Fig. 4 A, lanes
5 and 3) . Sequential digestions of the IgM-R with neuramin-
idase and O-glycanase did not result in further reduction in
size of the desialylated IgM-R molecule (Fig. 4 A, lane 1) .
In two-dimensional IEF gel analysis, the IgM-R isolated from
PMA-activated B CLL cells was resolved into a spot with
isoelectric points (pI) of 5.6-6.0 (Fig . 4 B) . The desialylated
19M-R molecule was shifted to a more basic spot with pI
> 7.2 (not shown) .
These findings indicate that the IgM-R on both pre-B and
B cells is a single sialoglycoprotein, withM, of "58,000 and
pI of 5.6-6.0, that has O-linked, but no N-linked, oligosac-
charides .
IgMC Regions Involved in Binding to the IgM-R .
￿
A quan-
titative immunofluorescence inhibition assay using various
Ig isotypes and IgM fragments as inhibitors was used to ex-
amine the binding specificity of the IgM-R. Human IgA4K
inhibited the binding of a mouse IgMic to PAM-activated
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697 pre-B cells in a dose-dependent manner, while human
IgG and IgA did not (Fig. 5 A) . The IgM binding was in-
hibited by Fc5ji fragments, but not by FabP . fragments (Fig.
5 B) . Fig. 6 A shows a representative inhibition profile for
IgM binding with a 64-fold excess of inhibitor proteins. To
confirm that the Fc portion of IgM molecules is the specific
ligand for the 58-kD cell surface receptor, the same panel
of inhibitors was used during immunoisolation of theIgM-R
molecule from activated pre-B cells. As shown in Fig. 6 B,
addition of a 100-fold excess of the intact IgM or its Fc5FA
fragments inhibited completely the binding ofthe 58-kD sur-
face protein to IgM-coated beads (lanes 4 and 2), while FabP,
fragments had no effect on ligand-mediated isolation of the
IgM-R molecule (lane 3) .
To determine which C region domain(s) of the isH chain
(CH) is involved in IgM-R binding, culture supernatants
from mouse hybridoma clones secreting mutant IgM mole-
cules with CH domain deletions were used as ligands in both
immunofluorescence and immunoisolation assays . The CHI
deletion mutant 43 bound to activated pre-B cells as well as
did the parental, intact IgM from Sp6 (Fig . 7 A) . A lesser,
but significant binding was also observed usingtwo different
CHI-2 deletion mutants, 128 and 427 . In contrast, the CHI-3
deletion mutant 208 and the CH4 deletion mutant 482 did
not exhibit binding activity. The same conclusion was drawn
from the immunoisolation assay in which the IgM mutants
with either CHI or CHI-2 deletion precipitated the 58-kD
IgM-R molecule from activated pre-B cells, whereas those
with either CHI-3 or CH4 deletion did not (Fig. 7 B) .
Phosphatidylinositol Linkage ofthe Cell Surface IgM-R .
￿
When
IgM-binding activity was examined by immunofluorescence
after treatment of PMA-activated pre-B cells with GPI-PLC,
the level of IgM binding was reduced by 89% . By compar-
Figure 4 . Characterization of the
IgM-R as an acidic sialoglycoprotein .
(A) Glycosidase digestion of IgM-R
molecule. The membrane lysates from
radiolabeled PM-activated CLL cells
were added to the wells precoated with
a mouse IgMK mAb (57.1 anti-DNP ;
lanes 1, 3, and S) or a mouse IgG1a
mAb (35 .3 anti-DNP; lanes 2, 4, and
6) . Bound materials. were digested
without (lanes S and 6) or with neur-
aminidase (lanes 3 and 4) or neuramin-
idase plus O-glycanase (lanes 1 and 2),
and analyzed by SDS-10%a PAGE. (B)
Two-dimensional gel electrophoretic
analysis of IgM-R molecule. IgM- or
IgG-bound membrane materials iso-
lated from radiolabeled PM-activated
CLL cells were separated first according
to isoelectric points in tube gels, and
then run according to molecular size
in slabs of SDS-PAGE .A 128
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Figure 5 .
￿
Evaluation of the Ig isotype specificity of the IgM-R . (A)
PMA-activated 697 pre-B cells (5 x 105) were incubated with the inhib-
itor human paraproteins : IgA1X (" ), IgG4X (0), or IgMA (O) before
incubation with the indicator mouse IgM mAb (anti-chicken la ; 0 .1
mg/ml) . Cell-bound IgM was detected by biotinylated rat anti-mouse K
mAb and PE-labeled streptavidin . Immunofluorescence was analyzed by
flow cytometry. Results were expressed as percent mean fluorescence esti-
matedby : 100 x [(X of IgM binding with inhibitors - X ofbackground
control)/(X of IgM binding without inhibitors - X ofbackground con-
trol)]; whereX indicates the mean fluorescence intensity value . (B) PMA-
activated 697 pre-B cells (5 x 105) were incubated with a human IgMrc
paraprotein (O) and its Fc5p (" ) and Fabp ([I) fragments for 30 min
at 4°C . The cells were then stained and analyzed by flow cytometry as
described above .
ison, GPI-PLC treatment reduced the expression of the GPI-
anchored DAF protein (50) by 70%, while the expression
of the transmembrane CD20 glycoprotein (see reference 51)
was unaffected (Fig . 8, lower panel) . GPI anchoring of the
IgM-R molecule was also indicated by SDS-PAGE analysis .
When radiolabeled pre-B cells were treated with GPI-PLC,
large amounts of the58-kD cell surface IgM-R were released
into the supernatant (Fig. 9, lanes 1 and 4) . In agreement
with the immunofluorescence results (Fig . 8, upperpane4,
a significant amount of theIgM-R was also released into the
medium in which radiolabeled cells were incubated at 37°C
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Figure 6.
￿
Fcp-dependent inhibition of IgM-R binding by IgM . (A)
Representative inhibitory activity of IgM and its fragments . PMAactivated
697 cells (5 x 10 5) were first incubated with a 64-fold excess of inhibitor
proteins, IgMK, Fc5,u, and Fab fragments for 30 min at 4°C . The cells
were then examined byimmunofluorescence for their capacity to bindmouse
IgM as described in Fig. 5 . Dashedlines indicate immunofluorescence profile
for background controls; dotted lines for IgM binding without inhibi-
tors ; solid lines for IgM binding with the test inhibitors . (B) The mem-
brane lysate from radiolabeled PMA-activated 697 cells (3 x 10 7) was in-
cubated with mouse IgM (Cla)-coated Sepharosebeads in the absence (lane
1) or the presence of100-fold excess of the following inhibitors: Fc5p (lane
2), Fabp (lane 3), and IgMK (lane 4) . Bound material was analyzed by
SDS-10% PAGE .
withoutGPI-PLC (Fig. 9, lane 2), suggesting the possibility
of endogenous PLC or pre-B cell protease activity.
Biosynthesis ofIgM-R Molecule.
￿
To determine whether the
IgM-R molecule is actively secreted, PMAstimulated pre-B
cells were metabolically labeled and the culture supernatant
and the cell lysate assessed for the presence of IgM-R mole-
cules . As shown in Fig . 10, none could be detected on IgM-
coated beads incubated with the culture supernatant of ei-
ther unstimulated pre-B cells (not shown) or those activated
with PMA (lane S), indicating no active secretion ofIgM-R
molecule. In contrast, an IgM-binding protein with essen-
tially the same molecular mass (57 ± 2 kD from 11 experi-
ments) as the surface IgM-R was identified in the cell lysate
of four pre-B cell lines and a pre-B ALL under both reducing
and non-reducing conditions (Fig . 10, lane 2) . The binding
of this molecule to the IgM-coated beads was inhibited by
addition of soluble IgM (Fig . 10, lane 3) . Unlike cell surface
IgM-R, the cytoplasmic form of the IgM-R was not obvi-
ously upregulated after PMA stimulation (data not shown) .
When pre-B cells were metabolically labeled in the presence
of tunicamycin, the molecular mass of the newly synthesizedDiscussion
E
z
m
u
Log Fluorescence
Log Fluorescence
IgM-R molecule was unaffected (Fig. 10, lane 10 vs. 11) . In
contrast, the tunicamycin treatment reduced the size of u
H chains from 79 to 68 kD, leaving the 78-kD BiP retention
molecule (52) behind (Fig . 10, lane 8 vs. 9) .
These experiments define the IgM-binding molecule of
-60 kD as an FcR on B lineage cells, its GPI linkage to the
Figure 8 .
￿
Susceptibility of IgM-R to PI-PLC assessed by flow cytom-
etry. PMA-activated 697 pre-B cells were incubated with or without PI-
PLC, and then examined for the expression of IgM-R, DAF, and CD20 .
(Top) Solid lines indicate profiles of cells incubated at 37°C without Pi-
PLC . Dotted lines indicate profiles of cells at 4°C without PI-PLC . Dashed
lines indicate background profiles for developing antibody controls, which
were the same for the two different cell treatments. Note modest reduc-
tion (49%) in mean fluorescence intensity of IgM-R, but not ofDAF
or CD2, profile after cell incubation alone. (Bottom) Solid lines indicate
profiles of cells incubated at 37°C with PI-PLC. Dotted lines indicate profiles
of cells incubated at 37°C without PI-PLC. Dashed lines indicate back-
ground profiles for developing antibody. Note the striking reductions in
mean fluorescence intensity ofIgM-R (89%) andDAF (70%) profiles after
PI-PLC treatment.
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Figure 7 . 19M CH domain(s) involved in
bindingto IgM-R . (A)PMAactivated697 cells
were incubated with CH deletional mutants or
their parental wild-type SP6 IgM (0 .5 ug/5
x 105 cells) . IgM binding (solid lines) was as-
sessed by immunofluorescence using bi-
otinylated rat anti-mouse K mAb and PE-
labeled streptavidin . CH deletional mutants
used here are 43 (CHI- , HIOLIO), 128 (CHI,2- ,
HL), 427 (CHI,2 - , H2L2), 208 (CHI-3, HL),
and 482 (CH4- , H2L2) . (B)The membrane ly-
satefrom radiolabeled PMA-activated 697 cells
was added to the wells precoated with the in-
dicated CH deletional mutants or intact mouse
IgM (SP6 andCIa) . Bound membrane proteins
were analyzed by SDS-10% PAGE.
cell surface, and the stages in B cell differentiation when it
can be expressed . , The restricted expression of FcIAR on
B-lineage cells indicated in our assay system is somewhat sur-
prising in view of the numerous reports describing IgM
binding by T cells. Early studies indicate that subpopulations
ofhumanT and B cells can bind IgM-coated ox erythrocytes
in an isotype-specific manner (14, 17, 18, 22, 23), and IgM-
bindingT cells have also been identified in chickens and mice
(15, 20, 24, 53) . Detection ofIgM-R on human T cells usu-
Figure 9.
￿
Release of membrane-bound
IgM-R into the supernatant after PI-PLC
treatment. Radiolabeled 697 pre-B cells
(PMA activated) were incubated with
(lanes 3 and 4) or without PI-PLC (lanes
1 and2), centrifuged , and then lysedwith
NP-40 1ysisbuffer. Cell supernatants (lanes
2 and 4) and cell lysates (lanes 1 and 3)
were examined for the presence ofIgM-R
using IgMic-coated Sepharose beads and
SDS-10% PAGE.
IgM-R OAF CD20
A
IgWR
N
OAF CD20 'Figure 10 .
￿
Biosynthetic analysis o£ IgM-R molecule . PMA-activated
697 pre-B cells (3 x 10 7) were metabolically labeled with 35S-Met and
35S.Cys (100 /ACi each) for 6 h in the absence (lanes 1-6, 8, and 10) or
presence (lanes 7, 9, and 11) of tunicamycin (2 .5 Irg/ml) . The 1% NP-40-
solubilized cell lysate (lanes 1-3 and 6-11) and the culture supernatant
(lanes 4 and 5) were subjected to immunoprecipitation with thefollowing
Ig-coated Sepharose beads : lanes 1 and 4, normal human IgG ; lanes 2,
5, 10, and 11, a human IgMK paraprotein ; lane 3, a human IgMK paraprotein
in the presence of a 100-fold excess of soluble mouse IgMK (Cla); lanes
6 and 7, 35.3 anti-DNP mAb (-ylK) ; lanes 8 and 9, SA-DA4-4 anti-human
1 mAb
(71K). Bound materials were analyzed by SDS-10% PAGE under
both nonreducing (not shown) and reducing conditions. The same results
were also obtained from three other pre-B cell lines (BLIN-1, SMS-SB,
Nalm 6) and a pre-B ALL (not shown) .
ally requires overnight incubation in appropriate media to
generate free binding sites, previously occupied by serum IgM
(14, 17, 22, 23) . More IgM antibodies are required to coat
ox erythrocytes in order to detect IgM-R on B cells (17, 22),
and the rosettes formed around B cells are more fragile than
theT cell-mediated rosettes (16, 17) . In contrast, subsequent
studies using an immunofluorescence assay reveal that heat-
aggregatedIgM binds exclusively to B cells from normal lym-
phoid tissues as well as to neoplastic B cells from patients
with CLL, hairy cell leukemia, orlymphoma (19, 54) . While
the differences in these earlier results may depend in part
on the methods used, it is noteworthy that IgM-R expres-
sion byB cells is consistently demonstrable regardless of the
assay method . Given the variety of FcyR and FceR mole-
cules that can be expressed by different cell types (8, 51), it
seems possible that the 58-kD FcuR identified on B-lineage
cells in the present study could be expressed on other types
of cells after appropriate stimulation or may be a member
of an IgM-R family. This issue will require further study
to reach final resolution, but the present data clearly indicate
a fundamental difference in expression of Fci.R by human
B and T cells .
The same FcuR was identified on cytoplasmic p. - ALL
cells, p.+ pre-B ALL or cell lines, IgM+ B cells or cell lines,
and isotype-switched CLL cells, indicating that this IgM-R
can be expressed throughout pre-B and B cell differentiation
and is not directly linked with IgM expression . The surface
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expression of FC,aR was more closely associated with the ac-
tivation status of cells. The level of its expression was in-
creased after exposure of B-lineage cells to the IgM ligand
or the phorbol ester PMA . The Fc/AR could also be detected
on subpopulations ofB cells obtained from tonsils and spleen
(17, 25), both of which contain activated B cells . In many
cases, leukemic cells of B-lineage constitutively expressed Fcp.R
on their surface in significant levels (16-19, 24, 54) . Fci4R
thus appears to belong to the family ofcell surface molecules
that have been characterized as activation antigens on B-lineage
cells (51) . Since some of these have been identified by IgM
mAb (see references 55 + 56), the assignation to this cate-
gory will require confirmation using assays assuring that an-
tibody binding to the activated B cells is mediated by the
Fab portion .
One objective ofthe present study was to obtain a suitable
cell source for isolation of the Fc/AR molecule for further
biochemical characterization . In this regard, several pre-B cell
lines were found to be excellent sources since they expressed
relatively large amounts of the Fc/AR after stimulation with
PMA . The Fc/AR was characterized as a 58-kD sialoglyco-
protein with O-linked oligosaccharides . The lack ofN-linked
glycosylation, an unusual feature for a cell surface glycopro-
tein, was suggested by two observations. First, the molec-
ular mass of iodinated surface FcaR was unaltered by treat-
ment with N-glycanase in various concentrations, and N-linked
oligosaccharides resistant to this enzyme have not been reported
(49) . Second, FcAR isolated from metabolically labeled cells
were identical in size both in the presence and absence of
tunicamycin . Removal of sialic acid residues with neuramin-
idase treatment instead resulted in a reduction of the apparent
molecular mass from 58 to 51 kD and a change in pl from
5.6-6.0 to >7.2 .
The Fc/AR appears to recognize configurations oftheIgM
molecule that are conferred by the CH3 and/or the CH4 do-
main(s) . First, Fcsj. fragments inhibit IgM binding to
FcjAR, whereas the Fabp, fragments do not . Fc5FA fragments
generated by the hot trypsin digestion of IgM are mainly
composed of the CH3_4 domains, since the major cleavage site
for this digestion is located within the CH2 domain (57) .
Second, IgM mutants with either CHt_3 or CH4 domain de-
letions could not bind the 58-kD Fc1.R.
It is interesting to contrast these results on FcAR expres-
sion by B-lineage cells in humans with those that have been
obtained in mice. While a murine FcuR molecule has not
yet been identified, the specific binding of IgM molecules
to B-lineage cells via their Fc portion has been well documented
using an immunofluorescence assay (21) . Studies with do-
main deletion mutants indicated an essential role for the CH3
domain in the IgM binding to murine B cells (21) . Only a
minor difference has been observed in the pattern of IgM-
binding capacity in the mouse in that pre-B cells and
IgM+/IgD+ B cells could bind IgM molecules, but isotype-
switched B cells and plasmacytomas or hybridomas appar-
ently could not (21) . In view of these findings, it seems likely
that the FcuR thatwe have characterized on human B-lineage
cells will be found to be conserved in mice .
The FcuR in humans appears to be anchored via phos-phatidyl-inositol to the surface ofpre-B cells, as indicated by
susceptibility to GPI-PLC enzymatic cleavage. GPI-PLC treat-
ment of thePMAactivated pre-B cells resulted in almost com-
plete elimination of Fc1AR expression and efficient release of
the 58-kD surface FcIAR into the medium. However, we also
noted that significant amounts of soluble Fcp,R with similar
molecular mass were released from PMA-activated pre-B cells
incubated without GPI-PLC . Similar spontaneous release has
been described for other GPI-anchored proteins : Qa-2 an-
tigen, acetylcholinesterase (AChE), Thy-1 antigen, FcyR III .
A soluble, but not actively secreted, form of the Qa-2 an-
tigen can be identified in the supernatant ofCon A-stimu-
lated T cells (58, 59) . AChE is released from certain areas
of the brain and adrenal chromaffin cells in response to var-
ious stimuli (60) . Similarly, the Thy-1 antigen onT cells (61)
and FcyR III on granulocytes (62) can be spontaneously
released from the cell surface. One possible mechanism for
this spontaneous release of GPI-anchored proteins is that it
is mediated by endogenous phospolipases, and the existence
of GPI-specific phospholipase D in plasma (39) would sug-
gest that this might occur in vivo . However, it is also note-
worthy that DAF, another GPI-anchored protein present on
pre-B cells, was not found to be released spontaneously in
our experiments. The selective nature of the release might
therefore favor the alternative possibility that the release could
be the consequence of proteolytic cleavage near the position
where the Fc/R molecule might be processed by exchanging
its COOH-terminal hydrophobic residues with the PI linkage
elements. This mechanism has been invoked to explain the
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